Market Research Logo

BioSeeker Group AB

BioSeeker Group is a business and competitive intelligence company for investment, venture and R&D management of biotechnology and pharmaceutical companies. It serves the needs of individuals, companies, and institutional clients with a diverse range of information and analysis services.

BioSeeker Group has a strong client focus providing decision-makers, investors, and management people with candid, credible research coverage on biotechnology and pharmaceutical companies. The firm is committed to creating value for clients by providing wisdom and high quality services that meet clients' needs. BioSeeker's clients and projects are kept confidential.

...Show More ...Show Less

222 Reports from BioSeeker Group AB

   
  • Targeting Natural Killer Cell Mediated Cytotoxicity in Cancer Drug Pipeline Update

    ... autologous cells undergoing various forms of stress, such as infection with viruses, bacteria, or parasites or malignant transformation. Although NK cells do not express classical antigen receptors of the immunoglobulin gene family, such as the ... Read More

  • Targeting Tight Junctions in Cancer Drug Pipeline Update

    ... of many different proteins that form large complexes. There are today 120 companies plus partners developing 122 tight junction targeting drugs in 466 developmental projects in cancer. In addition, there is 1 suspended drug and ... Read More

  • Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update

    ... homologs of Toll in Drosophila. Mammalian TLRs are expressed on innate immune cells, such as macrophages and dendritic cells, and respond to the membrane components of Gram-positive or Gram-negative bacteria. Pathogen recognition by TLRs provokes ... Read More

  • VEGF Signaling Pathway in Cancer Drug Pipeline Update

    ... transducer in both physiologic and pathologic angiogenesis. The binding of VEGF to VEGFR-2 leads to a cascade of different signaling pathways, resulting in the up-regulation of genes involved in mediating the proliferation and migration of ... Read More

  • RIG-I-like Receptor Signaling Pathway in Cancer Drug Pipeline Update

    ... result of intracellular viral replication is recognized by a family of cytosolic RNA helicases termed RIG-I-like receptors (RLRs). There are today 78 companies plus partners developing 55 RIG-I-like receptor signaling pathway targeting drugs in 166 ... Read More

  • NOD-like Receptor Signaling Pathway in Cancer Drug Pipeline Update

    ... than 20 members in mammals and plays a pivotal role in the recognition of intracellular ligands. There are today 113 companies plus partners developing 88 NOD-like receptor signaling pathway targeting drugs in 272 developmental projects ... Read More

  • Chemokine Signaling Pathway in Cancer Drug Pipeline Update

    ... the cell trafficking and thus are vital for protective host response. In addition, chemokines regulate plethora of biological processes of hematopoietic cells to lead cellular activation, differentiation and survival. There are today 232 companies plus ... Read More

  • PI3K-Akt Signaling Pathway in Cancer Drug Pipeline Update

    ... proliferation, growth, and survival. There are today 678 companies plus partners developing 1154 PI3K-Akt signaling pathway targeting drugs in 3721 developmental projects in cancer. In addition, there are 12 suspended drugs and the accumulated number ... Read More

  • Viral Carcinogenesis Drug Pipeline Update

    ... hepatitis C virus (HCV), human papilloma virus (HPV), human T-cell lymphotropic virus (HTLV-1) and Kaposi's associated sarcoma virus (KSHV) contribute to 10-15% of the cancers worldwide. Via expression of many potent oncoproteins, these tumor viruses ... Read More

  • Orphan Drugs in Oncology Drug Pipeline Update

    ... only to those cancer indications in which drugs are being granted orphan drug status, but also detailed insights in to their mechanism of action and developmental strategy. The orphan drug designation is designed to promote ... Read More

  • Lung Cancer Drug Pipeline Update

    ... two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe and ... Read More

  • Cancer Vaccines Drug Pipeline Update

    ... leaving the market wide open. There are today 314 companies plus partners developing 386 cancer vaccine drugs in 784 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ... Read More

  • Lymphoma Drug Pipeline Update

    ... cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 143 drugs. Lymphoma Drug Pipeline Update lists all drugs and gives you a ... Read More

  • Antibodies in Oncology Drug Pipeline Update

    ... the second wave in the lucrative field of therapeutic antibodies. There are today 542 companies plus partners developing 1308 antibody drugs in 3051 developmental projects in cancer. In addition, there are 4 suspended drugs and ... Read More

  • Leukemia Drug Pipeline Update

    ... in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 164 drugs. Leukemia Drug Pipeline Update lists all drugs and gives you ... Read More

  • Apoptosis in Oncology Drug Pipeline Update

    ... cells. There are today 460 companies plus partners developing 588 apoptotic drugs in 2586 developmental projects in cancer. In addition, there are 13 suspended drugs and the accumulated number of ceased drugs over the last ... Read More

  • Prostate Cancer Drug Pipeline Update

    ... eroded by the launch of various LHRH agonist depot formulations. Safety concerns with AstraZeneca`s Casodex (bicalutamide) have also seen a significant proportion of physicians switching to alternatives. Establishing the optimal timing of antihormonal therapy will ... Read More

  • Bladder Cancer Drug Pipeline Update

    ... early, the 5 year survival rate is 94%. There are today 139 companies plus partners developing 152 drugs targeting bladder cancer in development. In addition, there are 3 suspended drugs and the accumulated number of ... Read More

  • Renal Cancer Drug Pipeline Update

    ... cytokine therapy being less than 20% (RCC) in this patient cohort.The identification of biomarkers is set to revolutionize patient staging and prognosis by individualizing patient treatments and creating novel drug targets. There are today 243 ... Read More

  • Ovarian Cancer Drug Pipeline Update

    ... important secondary indication for existing and pipeline drugs. There are today 357 companies plus partners developing 438 drugs targeting ovarian cancer in development. In addition, there are 6 suspended drugs and the accumulated number of ... Read More

  • Pancreatic Cancer Drug Pipeline Update

    ... over the last years amount to another 136 drugs. Pancreatic Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 352 different ... Read More

  • Neuroendocrine Tumors Drug Pipeline Update

    ... of ceased drugs over the last years amount to another 24 drugs. Neuroendocrine Tumors Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked ... Read More

  • Head and Neck Cancer Drug Pipeline Update

    ... number of ceased drugs over the last years amount to another 59 drugs. Head And Neck Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified ... Read More

  • RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update

    ... or protein-based therapies. There are today 103 companies plus partners developing 131 RNA (miRNA, RNAi & siRNA) drugs in 198 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number ... Read More

  • Nucleic Acid Therapies in Oncology Drug Pipeline Update

    ... today 308 companies plus partners developing 381 nucleic acid therapy drugs in 775 developmental projects in cancer. In addition, there are 9 suspended drugs and the accumulated number of ceased drugs over the last years ... Read More

1 2 3 4 5 6 8

Research Assistance

Join Alert Me Now!

Sign Up

Find out more on our blog

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook